$AMDA: Amedica Receives Positive Nasdaq Listing De
Post# of 22755
10/17/17 | GlobeNewswire
Amedica Receives Positive Nasdaq Listing Decision
SALT LAKE CITY, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq: AMDA) (the "Company", an innovative biomaterial company that develops and manufactures silicon nitride as a platform for biomedical applications, announced today that the Nasdaq Hearings Panel (the "Panel" has granted the Company's request for an extension within which to evidence full compliance with the criteria for continued listing on The Nasdaq Capital Market, including the filing requirement and the $1.00 closing bid price requirement. The Company's continued listing on Nasdaq is subject to the Company filing its Forms 10-Q for the quarterly periods ended March 31, 2017 and June 30, 2017 with the SEC by October 31, 2017, and the Company evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days by November 30, 2017. The Company expects to timely satisfy the deadlines set forth in the Panel's decision.